Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer

NCT ID: NCT03334500

Last Updated: 2025-09-10

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-07-14
• Study Completion Date: 2026-07-16

Brief Summary

Men with a history of prostate cancer may be in this study. Subjects recommended for a prostatectomy or oligometastectomy will undergo PET/CT imaging using a novel radiotracer [18F]FTT to evaluate PARP-1 activity in known or suspected sites of primary or metastatic disease. Imaging will be compared with pathology results, including additional research assays when possible.

Conditions

Prostate Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1

Gleason 6 (n=10)

Group Type: EXPERIMENTAL

[18F]FluorThanatrace

Intervention Type: DEVICE

Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg.

Poly(ADP Ribose) Polymerase 1

Intervention Type: DRUG

Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.

Cohort 2

Gleason 7-8 (n=10)

Group Type: EXPERIMENTAL

[18F]FluorThanatrace

Intervention Type: DEVICE

Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg.

Poly(ADP Ribose) Polymerase 1

Intervention Type: DRUG

Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.

Cohort 3

Gleason 9 or oligometastic disease (n=10)

Group Type: EXPERIMENTAL

[18F]FluorThanatrace

Intervention Type: DEVICE

Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg.

Poly(ADP Ribose) Polymerase 1

Intervention Type: DRUG

Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.

Interventions

[18F]FluorThanatrace

Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg.

Intervention Type: DEVICE

Poly(ADP Ribose) Polymerase 1

Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.

Intervention Type: DRUG

Other Intervention Names

18F-FTT; PARP 1

Eligibility Criteria

Inclusion Criteria

• Participants will be ≥ 18 years of age
• Biopsy proven prostate cancer
• Must meet one of the following criteria:

1. At least two tissue cores containing at least 50% tumor (per pathology report) OR

2. At least one lesion that is 1 cm or greater in size by standard imaging (e.g. ultrasound, MRI, CT). Only one type of imaging is required to show a lesion of 1 cm or greater in order for the patient to be eligible to participate in this study.

• Recommended for clinically indicated radical prostatectomy or oligometastectomy
• Willing to allow use or collection of pathology tissue for the purposes of research from either clinical biopsy or surgical procedure (if adequate tissue is available)
• Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria

• Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
• Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.
• Only individuals (aged 18 or over) who can understand and give informed consent will be approached to participate in this study. Individuals who are considered to be mentally disabled will not be recruited for this study. All subjects must understand and be able to give informed consent. We will not be using specific methods to assess decisional capacity. Economically disadvantaged persons will not be vulnerable to undue influence, as this study offers no compensation. All individuals will be told that their choice regarding study participation will in no way change their access to clinical care. This should negate any undue influence or coercion. Women, children, fetuses, neonates, or prisoners are not included in this research study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abramson Cancer Center at Penn Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dan Pryma, MD

Role: PRINCIPAL_INVESTIGATOR

Abramson Cancer Center at Penn Medicine

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Countries

United States

Other Identifiers

UPCC 13817

Identifier Type: -

Identifier Source: org_study_id